NEW YORK (GenomeWeb) – Veracyte announced yesterday that its Afirma Gene Expression Classifier has received positive policy coverage decisions by Health Care Service Corporation, an independent licensee of the Blue Cross Blue Shield Association, and New York's Excellus BlueCross BlueShield.

The Afirma GEC employs a 142-gene signature to identify benign thyroid nodules in patients whose fine needle aspiration biopsies are deemed indeterminate following traditional cytopathology review and thus face a potentially unnecessary diagnostic surgery.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.